The Company and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Basic and Diluted Net Income per Ordinary Share Computation

Basic and diluted net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc were computed as follows (in thousands, except per share amounts):

	Three Months Ended March 31,
	2014			2013
Numerator:
Net income (loss) attributable to Jazz Pharmaceuticals plc	$	(92,650	)	$	43,425
Denominator:
Weighted-average ordinary shares used in calculating net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc - basic	58,526			58,358
Dilutive effect of employee equity incentive and purchase plans	—			1,496
Dilutive effect of warrants	—			1,657
Weighted-average ordinary shares used in calculating net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc - diluted	58,526			61,511
Net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc:
Basic	$	(1.58	)	$	0.74
Diluted	$	(1.58	)	$	0.71

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share

The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc for the periods presented because including them would have an anti-dilutive effect (in thousands):

	Three Months Ended March 31,
	2014	2013
Options to purchase ordinary shares and RSUs	5,491	2,352
Warrants to purchase ordinary shares	1,257	—
Ordinary shares under ESPP	141	—